Table 3.
Results of analyses by disease
| 3–1. ERG responses before and after injection in eyes with AMD | ||||
| AMD n = 37 (male, 24; female, 13) | ||||
| mean age | 74.1 ± 8.6 y.o. | |||
| injected eye | Phase 1 | Phase 2 | Phase 3 | repeated measure test |
| implicit time | 29.9 ± 1.8 | 30.4 ± 1.6a | 30.8 ± 2.14a | p = 0.00009 |
| (msec.) | p = 0.025 | p = 0.00001 | ||
| amplitude | 9.0 ± 5.7 | 8.1 ± 6.4 | 9.0 ± 6.3 | p = 0.484 |
| (uV) | p = 1 | p = 1 | ||
| non-injected eye | Phase 1 | Phase 2 | Phase 3 | repeated measure test |
| implicit time | 29.5 ± 2.5 | 30.4 ± 2.1a | 30.6 ± 2.4a | p = 0.00097 |
| (msec.) | p = 0.023 | p = 0.0017 | ||
| amplitude | 10.1 ± 7.2 | 9.6 ± 7.3 | 9.8 ± 6.2 | p = 0.853 |
| (uV) | p =1 | p =1 | ||
| 3–2. ERG responses before and after injection in eyes with DME | ||||
| DME n = 24 (male, 14; female, 10) | ||||
| mean age | 59.9 ± 11.3 y.o. | |||
| injected eye | Phase 1 | Phase 2 | Phase 3 | repeated measure test |
| implicit time | 33.6 ± 3.2 | 34.2 ± 3.2 | 34.7 ± 3.1a | p = 0.00036 |
| (msec.) | p = 0.19 | p = 0.0003 | ||
| Amplitude | 8.0 ± 5.9 | 7.1 ± 5.8 | 7.6 ± 5.9 | p = 0.45 |
| (uV) | p = 0.94 | p = 0.96 | ||
| non-injected eye | Phase 1 | Phase 2 | Phase 3 | repeated measure test |
| implicit time | 33.6 ± 3.1 | 34.1 ± 3.1 | 34.3 ± 3.4a | p = 0.0493 |
| (msec.) | p = 0.327 | p = 0.014 | ||
| Amplitude | 7.5 ± 5.1 | 7.2 ± 5.5 | 7.8 ± 5.6 | p = 0.495 |
| (uV) | p = 1 | p = 1 | ||
| 3–3. ERG responses before and after injection in eyes with ME associated with RVO | ||||
| RVO with ME n = 18 (male, 6; female, 12) | ||||
| mean age | 70.1 ± 14.9 y.o. | |||
| injected eye | Phase 1 | Phase 2 | Phase 3 | repeated measure test |
| implicit time | 30.7 ± 3.7 | 31.3 ± 3.4 | 31.6 ± 3.79a | p = 0.00692 |
| (msec.) | p = 0.1125 | p = 0.0027 | ||
| Amplitude | 8.9 ± 5.7 | 8.5 ± 5.8 | 12.9 ± 14.7 | p = 0.214 |
| (uV) | p = 1 | p = 0.68 | ||
| non-injected eye | Phase 1 | Phase 2 | Phase 3 | repeated measure test |
| implicit time | 28.4 ± 1.9 | 28.6 ± 2.0 | 28.9 ± 2.3 | p = 0.231 |
| (msec.) | p = 0.85 | p = 0.53 | ||
| amplitude | 10.5 ± 6.4 | 10.8 ± 6.5 | 11.2 ± 6.7 | p = 0.573 |
| (uV) | p = 1 | p = 0.96 | ||
The results of 28 Hz flicker electroretinogram components classified by disease. The ERGs were recorded before the injection (Phase 1), within 2 h after the injection (Phase 2), and 2 to 24 h after the injection (Phase 3)
mean ± standard deviation
a; significant difference by the repeated measure test and by the post hoc test compared with Phase 1
AMD age-related macular degeneration;
DME diabetic macular edema;
RVO with ME retinal vein occlusion with macular edema